@FRubinoMD@NeilFlochMD@Nature I donโt quite understand this framework. We donโt wait for end organ damage to diagnosis hypertension or diabetes. We use cutoffs that on population level correlate with end organ dysfunction.why diff for obesity? Why wait for end organ damage?
@MichaelMindrum@DrMarthaGulati Darn - i wonder why health Canada or Novo never pursue the 2.0mg dosing for DM2. 100$ for a 4mg pen is still awesome though!
@Ashwinreads There can be somewhat of a trade off- look at cagri sema. Their flexible titration came with much better tolerability but result was lessened with less patients on max dose. They would have needed to extend trial with more flexible titration to capture the plateau
@mcuban with Canada launching generic ozempic; any plans for @costplusdrugs to import it under sec 804 of FD&C act. My patients could really benefit!!
@BioLayne You can tell them. But should follow up by the physiology of obesity makes a sustained calorie deficit (real or perceived) very hard to achieve and maintain in >90% of individuals. And itโs ok to use a GLP1 to increase your odds of success with this.
@MichaelMindrum Why low dose rosu + ezetimibe unless you have side effects?. Are you concerned about the insulin resistance ? Personally just take high dose rosuva, donโt feel compelled to add eze with ldl <70 but also think itโs a low risk med if patients want to add.
@DrMarthaGulati@VietHeartPA Itโs a great new addition and more convenient but definitely needs a lower price give much lower effectiveness. Wonโt be a huge part of my practice at this price point
@allisonoconn@cardiojaydoc02@SR_DeshpandeMD Some estimate that up to 50% of medications contain some amount of animal derived products (think gelatin etc). While the concept is fair itโs not incredibly realistic to do this in reality IMO. Obvious pt can refuse but not a routine consideration
@hvanspall Thanks for sharing this story.Very moving.What shocks me the most is the silence and lack of accountability after clear error.I hope even if they didnโt have the humility to own up to their mistake that they rmeber your dad in their decisions going fwd.
@cremieuxrecueil Many patients cannot access GLp1, are under responders or need want >40-50% total body weight loss. There will still be demand for Bariatric surgery for many decades until we get Enough accessible treatments and intervene earlier on in disease
@drjohnm This is not an evidence based take. Hundreds of trials show that this is not true of lifestyle Alone due to chronic neurohormonal and metabolic changes following weight loss.
@BevTchangMD Am far from a basic scientist- does this functional receptor assay test account for the dramatically longer half life of synthetic agonists vs native ? Ie it could be 3x less potent than native but itโs sticking around for days, not minutes .